BIOCHIPS MCP-1026
A GLOBAL STRATEGIC BUSINESS REPORT
CONTENTS
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
A. DNA Chips I-3
B. Protein Chips I-3
C. Lab Chips I-4
II. EXECUTIVE SUMMARY
1. Industry Overview II-1
Promising Biochips Promote Biological Research II-1
Market Scenario across Products and Regions II-1
DNA Chips Lead the Application Front II-2
Probable Industry Directions II-2
Biochip Technology Boosts Personalised Medicine II-3
Biochip Technology Spreads beyond Pharma Industry II-3
Protein Chips to Shape the Future II-4
Proteomics “ Chip” into Biochip Technology II-4
Towards Increasing Minaturization II-4
European Advancements Set Diagnostic Procedures II-5
Competitive Scenario II-5
Major Participants II-5
Roche and Affymetrix Taste Success in the Diagnostics Market II-6
Growing Partnerships between Pharma and Biotech Companies II-6
Tech Giants Join the Biochip Fray II-7
2. Product Overview II-8
Biochips - Complex Blend of Biochemistry and Electronics II-8
Historical Perspective II-8
Lab-on-a-chip: An Enabled Technology II-10
Utility II-10
Evolution and Segmentation II-10
Differing Perspectives II-10
Classification of Biochips II-11
Manufacturing Systems Used in Biochip Manufacture II-12
Working of a Biochip II-12
A Functional Model II-13
Cocktail of Disparate Technically Specialized Applications II-13
Biochips: By-product of Multi-disciplinary Sciences II-13
Nanotechnology II-13
BioMEMS II-14
Microfluidics II-15
Micro Total Analysis System II-15
3. Biochip And Microarray Construction II-16
Chip Architecture II-16
Essence of a Biochip II-16
Concept of a Microarray II-16
Microarray Modules II-16
High Degree of Automation Spurs Biochips Use II-17
Microfabrication Technology in Biochips made from Polymer and
Plastics II-17
Micro-optics in Biochips II-17
Liquid Handling Through Micro-Dispensers II-18
Capillary Electrophoresis and Electrochemical Detectors II-18
Other Technologies II-18
Management of Bio-information II-18
Scanning II-18
Microarray Database Management II-19
Classification of DNA Chips II-19
General Description of Spotted cDNA Microarrays II-19
Spotted DNA Arrays II-19
Spotted cDNA Versus Spotted Oligonucleotide Arrays II-19
Limitations of Conventional cDNA Microarrays II-20
Protein Biochips II-20
General Applications of Protein Biochips II-21
Challenges in the Design of a Protein Biochip II-21
Limitations of Protein Chip Technology II-21
Advances by Companies II-22
Concluding Remarks for Protein Biochips II-22
4. Applications of Biochips II-23
Biochip Uses II-23
Biochips and Pharmaceutical Investigation II-24
Biochips and Medical Diagnostics II-24
Advantages of Biosensor Chip Technology II-25
Biochips and Forensics II-25
Biochips and Transplantation Screening II-25
Biochips and Identity Testing II-25
Biochips and Water and Environmental Testing II-25
Food Industry II-25
5. Trends II-26
Industry Characteristics II-26
New Products and Players to Drive Market II-26
Key Forces Boosting the Industry II-26
Industry Structure II-26
Industry Challenges II-27
Price Dearness Pauses Biochips Growth II-27
Current Approaches to Biochips II-27
The Business of Biochips II-27
Technological Trends II-28
Sensitivity II-28
Microfabrication II-29
Density II-29
Integrated Chips II-29
Patent Trends II-29
Patent Applications II-30
Table 1: Biochips Patent Applications (2003)-Percentage
Breakdown by Geographic Region for US, China, Japan,
Germany, South Korea, UK and Others (includes corresponding
Graph/Chart) II-30
6. Next Generation Technology II-31
Microfluidics Using CD-ROM Technology II-31
7. Product Innovations and Developments II-32
Affymetrix Introduces Complete Cytogenetic Solution II-32
Agilent Unveils 244K CGH Micro-Array II-32
Randox Unveils World’s First Protein Biochip II-32
Randox Introduces Thyroid Array Biochip II-32
Sigma Launches ChIP Kit II-33
Randox Develops Biochip for Synthetic Steroids II-33
US and Czech Scientists to Develop Biochips for Detecting Cancer II-33
febit Introduces New Geniom Biochip II-34
Agilent Introduces Additions to the HPLC-Chip Line for
Proteomics II-34
Progenika Develops BLOODchip II-35
Roche Introduces Gene Expression Services and Arrays II-35
Stratos Biosystems Develops New EC-Affinity Biochips II-35
Affymetrix Unveils Affymetrix GeneChip Command Console Software II-36
Affymetrix Introduces GeneChip Mouse and Rat Gene 1.0 ST Arrays II-36
Affymetrix Unveils Genome-Wide Human SNP Array 6.0 II-36
Caliper Life Sciences Launches High Throughput RNA Assay II-37
Applied Biosystems Unveils DNA Tools II-37
febit Launches Geniom RT Analyzer II-37
Austrian Research Center Develops New Biochip Surface II-38
Researchers Develop Biochips to Eliminate Animal Testing II-38
Progenika Biopharma Launches IBD DNA II-38
Bioident Develops New Lab-on-a-Chip Nanotiter Plate Prototype II-39
Ilochip and University of Denmark Develop a Biochip for
Faster Bird Flu Detection II-39
CombiMatrix Develops a Biochip for Leukemia Analysis II-39
Affymetrix Launches New Tiling Arrays for Mapping Whole-
Genome Transcript II-39
Roche Plans to Launch AmpliChip in Japan II-40
Caliper Life Sciences Unveils Desktop Profiler II-40
Massachusetts Institute of Technology Develops Portable Lab
on a Chip II-40
Optical Device to Develop Lab-on-a-Chip II-40
Agilent Launches Five New HPLC Chips II-41
Protagen AG Launches New Protein Biochips II-41
Fluidigm Releases the 8.96 TOPAZ Screening Chip II-41
Affymetrix Releases Chip-on-Chip Array II-41
DNA Chip Research Launches High Sensitivity DNA Chip II-41
DNA Chip Research and HitachiSoft Unveils AceGene II-41
Affymetrix Introduces GeneChip® Human Exon Array II-41
Affymetrix Announces Launch of GeneChip(R) Array Station II-42
Affymetrix Unveils GeneChip® Human Mapping 500K Arra Set II-42
Affymetrix Introduces GeneChip-Compatible™ Application Program II-42
Affymetrix Launches GeneChip(R) Scanner II-42
Hitachi Develops RFID Sensor Chip for DNA Analysis II-43
Canon Develops DNA Chip on Inkjet Printer Technology II-43
Biacore Introduces Array-Based Protein Interaction Analysis
Systems II-43
Caliper Launches Protein Express Assay for Electrophoresis
System II-43
Affymetrix Rolls Out GeneChip(R) Globin-Reduction Kits and
Protocol II-43
Biacore Introduces Next Generation System for Protein
Interaction Analysis (Sweden) II-44
Affymetrix and Invitrogen Launch Reagents for GeneChip
Expression Array Platform II-44
Amersham Biosciences Extends CodeLink Range II-44
Ciphergen Showcases ProteinChip System- Series 4000 II-44
Affymetrix Rolls Out Plasmodium/Anopheles Genome GeneChip(R)
Array II-45
SIRS-Lab Showcases Lab-Arraytor(R) II-45
Affymetrix Unveils GeneChip(R) Array for Malaria Study II-45
Caliper Extends Portfolio of LabChip Microfluidic Systems II-45
Affymetrix Launches World’s First Diagnostic Microarray
System (Europe) II-45
Ushio’s biochip Machine for BioMEM and MicroTAS (Japan) II-46
Invitrogen Unveils Yeast ProtoArray II-46
Randox Showcases biochip Technology for Clinical Diagnostics
(UK) II-46
Zyomyx Introduces Murine Cytokine Biochip (US) II-46
Invitrogen Launches ProtoArray Human Protein Microarray II-47
Affymetrix Launches Plasmodium Genome GeneChip(R) II-47
8. Recent Industry Activity II-48
DNA Chip Acquires HuBit’s Gene Analysis Business II-48
Affymetrix Acquires USB II-48
Roche NimbleGen Forms Alliance with BioDiscovery to Provide
CGH Solutions II-48
Illumina Announces Partnership with Genpathway for ChIP
Sequencing Services II-48
Jiangsu and IMDi Diagnosis to Establish Joint Venture II-49
Plexera Biosciences Enters into an Option Deal with Auguron II-49
Affymetrix and Avesthagen Enter into an Agreement II-50
Roche NimbleGen and Affymetrix Announce Expansion of License
Agreement II-50
Proteomika and Auguron Biosciences Ink Option Agreement II-50
Gentel Biosciences and Eppendorf Enter into Global License
Agreement II-51
GATC Biotech Establishes New Subsidiary II-51
Procognia Spins off Sense Proteomic II-52
Johns Hopkins University Purchases MassARRAY System II-52
Yale University Purchases MassARRAY System II-52
Korea’s NIH Extends KARE Project with Affymetrix Technology II-52
febit Obtains US Patent for Hybselect, a Microfluidic
Extraction Method II-53
Roche Takes Over NimbleGen II-53
GenTel BioSciences Acquires Protein Chip Platform Assets of GSK II-54
Advanced Liquid Logic Acquires Nanolytics II-54
Applied Microarrays Acquires Select GE Healthcare’s Assets II-54
Canon, Toshiba and Other Companies to Join Hands for Biochips II-55
BioChip Innovations Signs Research Collaboration Agreement
with IME II-55
Protagen Enters into a Partnership to Develop Antibodies II-56
Spanish Society of Rheumatology Enters into Collaboration
with Progenika II-56
Affymetrix and Partners Healthcare Extend Collaboration II-56
Agencourt, NuGEN and Affymetrix Clinical Services Collaborate II-57
Affymetrix Inks Licensing Agreement with Empire Genomics II-57
Caliper Enters into a Licensing Agreement with Monogram
Biosciences II-57
Affymetrix and IPSOGEN Sign Agreement II-58
bioMérieux and NuGEN Enter into Supply and Cross-License
Agreement II-58
VWR and CapitalBio Enter into a Distribution Agreement II-59
C3B Bags Contract from Department of Defense to Develop an
Implantable Biochip II-59
UCL Subsidiary and Roche Diagnostics Ink Licensing Deal II-59
Affymetrix Establishes the European Cytogenetic Research
Initiative II-59
Fluidigm Establishes New Development Center II-60
Daiichi Pure Chemicals Applies for Approval to Market DNA
Micro-array II-60
GE Healthcare Snaps Up Biacore II-60
Bio-Rad Acquires Ciphergen’s Life Science Research Business II-61
Sysmex to Form Partnership with Affymetrix II-61
Daiichi, Toshiba Hokuto and Toshiba Join Hands II-61
Affymetrix Collaborates with Zhejiang California Nanosystem
Institute II-61
Merck Sharp & Dohme and Shanghai Biochip Enter into Co-
operation Agreement II-62
Toshiba Signs Licensing Agreement with Antara BioSciences II-62
MUSC Signs LOI with Lumera II-62
AVIVA Inks Agreement with Japan’s Cosmo Bio II-62
Lumera Signs Collaborative Agreement with Harvard Medical
School II-63
Whatman Receives CE Mark for CombiChip II-63
IDIBAPS Led Project Receives Approval from European Union II-64
Toray to Establish DNA Chip Business II-64
Protagen Forays into the US Market II-64
Biacore Expands Operations into Chinese Market II-64
Nisshinbo to Replace Glass with Resin in DNA Production II-64
OCIMUM Acquires a Division of MWG Biotech AG II-65
Biacore Acquires FLEXChip from HTS BioSystems II-65
Qiagen Acquires Assets of LumiCyte II-65
BD Sells Clontech II-65
Affymetrix Acquires ParAllele BioScience II-65
Biacore Acquires FLEXChip System from HTS BioSystems II-66
Caliper Signs Purchase Agreement with Amphora II-66
Bio-Rad Inks Agreement with Caliper II-66
Toray Enters Joint Research Agreement with DNA Chip Research II-66
Ciphergen and Quest Diagnostics Partner for Proteomic
Diagnostic Tests II-66
Affymetrix and bioMerieux Extend Agreement II-67
bioMérieux Extend Collaboration Agreement with ExonHit
Therapeutics II-67
Agilent Technologies Licenses Caliper's LabChip(R) Technology II-67
Caliper and Predicant Biosciences Forge Licensing Agreement II-68
IntegraGen Signs Agreement with La Ligue Nationale Contre le
Cancer II-68
GSK Selects Affymetrix GeneChip® 500K Array for Whole- Genome
Association Studies II-68
Affymetrix Supplies GeneChip Technology to Veridex II-68
GE Acquires Amersham PLC II-68
ViroLogic Merges with Aclara Biosciences II-69
Invitrogen Accredits Protein Chip Intellectual Property From
Zyomyx II-69
Toshiba Collaborates with Osaka University II-69
Siemens, Infineon and Dr. Hintsche Plan Extended Alliance on
Biochip Technology II-69
Intel Eyes Biochips II-70
APAF and LumiCyte Join Hands in Proteomic Discovery II-70
Affymetrix and Caliper Life Sciences Join Forces for Target
Preparation II-70
Affymetrix and TGen Collaborate to Offer Genotyping Services II-70
Affymetrix Licenses GeneChip Technology to Veridex II-71
Affymetrix Grants Access to Aventis for GeneChip(R) Platform II-71
GeneChip Technology to Aid Neurological Disease Detection II-71
Affymetrix, ParAllele and Cambridge University Join Hands For
Extensive Genotyping II-71
9. Focus on Select Global Players II-72
Affymetrix (US) II-72
Applied Biosystems Group (US) II-72
Biomerieux (France) II-72
Bio-Rad Laboratories, Inc. (US) II-73
Caliper Technologies Corp (US) II-73
Cepheid Inc. (US) II-73
GE Healthcare Ltd (UK) II-74
Takara Bio, Inc. (Japan) II-74
Zyomyx (US) II-74
10. Global Market Perspective II-75
Table 2: World Recent Past, Current & Future Analysis for
Biochips by Geographic Region - US, Canada, Japan, Europe,
and Rest of World Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2000 through 2010
(includes corresponding Graph/Chart) II-75
Table 3: World Long-term Projections for Biochips by
Geographic Region - US, Canada, Japan, Europe, and Rest of
World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) II-76
Table 4: World 10-Year Perspective for Biochips by Geographic
Region - Percentage Breakdown of Dollar Sales for US, Canada,
Japan, Europe, and Rest of World Markets for Years 2003, 2008
& 2012 (includes corresponding Graph/Chart) II-77
Table 5: World Recent Past, Current & Future Analysis for DNA
Chips by Geographic Region - US, Canada, Japan, Europe, and
Rest of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) II-78
Table 6: World Long-term Projections for DNA Chips by
Geographic Region - US, Canada, Japan, Europe, and Rest of
World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) II-79
Table 7: World 10-Year Perspective for DNA Chips by Geographic
Region - Percentage Breakdown of Dollar Sales for US, Canada,
Japan, Europe, and Rest of World Markets for Years 2003, 2008
& 2012 (includes corresponding Graph/Chart) II-80
Table 8: World Recent Past, Current & Future Analysis for
Protein Chips by Geographic Region - US, Canada, Japan,
Europe, and Rest of World Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2000 through
2010 (includes corresponding Graph/Chart) II-81
Table 9: World Long-term Projections for Protein Chips by
Geographic Region - US, Canada, Japan, Europe, and Rest of
World Markets Independently Analyzed with Annual Sales Figures
in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) II-82
Table 10: World 10-Year Perspective for Protein Chips by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, and Rest of World Markets for
Years 2003, 2008 & 2012 (includes corresponding Graph/Chart) II-83
Table 11: World Recent Past, Current & Future Analysis for Lab
Chips by Geographic Region - US, Canada, Japan, Europe, and
Rest of World Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2000 through 2010
(includes corresponding Graph/Chart) II-84
Table 12: World Long-term Projections for Lab Chips by
Geographic Region - US, Canada, Japan, Europe, and Rest of
World Markets Independently Analyzed with Annual Sales Figures
in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) II-85
Table 13: World 10-Year Perspective for Lab Chips by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, and Rest of World Markets for Years
2003, 2008 & 2012 (includes corresponding Graph/Chart) II-86
III. MARKET
1. The United States III-1
A.Market Analysis III-1
Outlook III-1
Biochips Market Overview III-1
Time Saving Biochips - All Set to Grow III-1
Multiple Applications of Biochips Drive Sales III-1
Biochip Market Faces Challenges III-2
Product Developments/Launches III-2
Strategic Corporate Developments III-10
Key Player Review III-22
Affymetrix III-22
Applied Biosystems Group III-22
Bio-Rad Laboratories, Inc. III-22
Clontech Laboratories, Inc. III-23
Caliper Life Sciences, Inc. III-23
Cepheid III-23
Zyomyx III-24
B.Market Analytics III-24
Table 14: US Recent Past, Current & Future Analysis for
Biochips by Product Segment - DNA Chips, Protein Chips and
Lab Chips Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010
(includes corresponding Graph/Chart) III-24
Table 15: US Long-Term Projections for Biochips by Product
Segment - DNA Chips, Protein Chips and Lab Chips Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) III-25
Table 16: US 10-Year Perspective for Biochips by Product
Segment - Percentage Breakdown of Dollar Sales for DNA
Chips, Protein Chips and Lab Chips Markets for Years 2003,
2008 & 2012 (includes corresponding Graph/Chart) III-25
2. Canada III-26
Market Analysis III-26
Table 17: Canadian Recent Past, Current & Future Analysis
for Biochips by Product Segment - DNA Chips, Protein Chips
and Lab Chips Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2000 through 2010
(includes corresponding Graph/Chart) III-26
Table 18: Canadian Long-Term Projections for Biochips by
Product Segment - DNA Chips, Protein Chips and Lab Chips
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) III-27
Table 19: Canadian 10-Year Perspective for Biochips by
Product Segment - Percentage Breakdown of Dollar Sales for
DNA Chips, Protein Chips and Lab Chips Markets for Years
2003, 2008 & 2012 (includes corresponding Graph/Chart) III-27
3. Japan III-28
A.Market Analysis III-28
DNA Chip Based on Printing Technology III-28
DNA Chips to Reveal Links Among Genes III-28
A leading Japanese Biochip Player - Takara Shuzo III-29
ICAN ™ Technology for Large-Scale Production of DNA Fragments III-29
Product Launches III-30
Strategic Corporate Developments III-30
Takara Bio Inc - A Key Player III-33
B.Market Analytics III-34
Table 20: Japanese Recent Past, Current & Future Analysis
for Biochips by Product Segment - DNA Chips, Protein Chips
and Lab Chips Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2000 through 2010
(includes corresponding Graph/Chart) III-34
Table 21: Japanese Long-Term Projections for Biochips by
Product Segment - DNA Chips, Protein Chips and Lab Chips
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) III-35
Table 22: Japanese 10-Year Perspective for Biochips by
Product Segment - Percentage Breakdown of Dollar Sales for
DNA Chips, Protein Chips and Lab Chips Markets for Years
2003, 2008 & 2012 (includes corresponding Graph/Chart) III-35
4. Europe III-36
A.Market Analysis III-36
Biochips Outlook in Europe III-36
European Advancements Shape Diagnostic Procedures III-36
Product Launches III-37
Strategic Corporate Developments III-37
B.Market Analytics III-38
Table 23: European Recent Past, Current & Future Analysis
for Biochips by Geographic Region - France, Germany, UK, and
Rest of Europe Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2000 through 2010
(includes corresponding Graph/Chart) III-38
Table 24: European Long-Term Projections for Biochips by
Geographic Region - France, Germany, UK, and Rest of Europe
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) III-39
Table 25: European 10-Year Perspective for Biochips by
Geographic Region - Percentage Breakdown of Dollar Sales
for France, Germany, UK, and Rest of Europe Markets for
Years 2003, 2008 & 2012 (includes corresponding
Graph/Chart) III-40
Table 26: European Recent Past, Current & Future Analysis
for Biochips by Product Segment - DNA Chips, Protein Chips
and Lab Chips Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2000 through 2010
(includes corresponding Graph/Chart) III-41
Table 27: European Long-Term Projections for Biochips by
Product Segment - DNA Chips, Protein Chips and Lab Chips
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) III-41
Table 28: European 10-Year Perspective for Biochips by
Product Segment - Percentage Breakdown of Dollar Sales for
DNA Chips, Protein Chips and Lab Chips Markets for Years
2003, 2008 & 2012 (includes corresponding Graph/Chart) III-42
4a. France III-43
A.Market Analysis III-43
Strategic Corporate Developments III-43
Biomerieux - A Major Player III-44
B.Market Analytics III-45
Table 29: French Recent Past, Current & Future Analysis for
Biochips by Product Segment - DNA Chips Protein Chips and
Lab Chips Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-45
Table 30: French Long-Term Projections for Biochips by
Product Segment - DNA Chips, Protein Chips and Lab Chips
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) III-45
Table 31: French 10-Year Perspective for Biochips by
Product Segment - Percentage Breakdown of Dollar Sales for
DNA Chips, Protein Chips and Lab Chips Markets for Years
2003, 2008 & 2012 (includes corresponding Graph/Chart) III-46
4b. Germany III-47
A.Market Analysis III-47
Berlin, Brandenburg and Biochips III-47
Product Launch III-47
Strategic Corporate Developments III-48
B.Market Analytics III-49
Table 32: German Recent Past, Current & Future Analysis for
Biochips by Product Segment - DNA Chips, Protein Chips and
Lab Chips Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) III-49
Table 33: German Long-Term Projections for Biochips by
Product Segment - DNA Chips, Protein Chips and Lab Chips
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) III-49
Table 34: German 10-Year Perspective for Biochips by
Product Segment - Percentage Breakdown of Dollar Sales for
DNA Chips, Protein Chips and Lab Chips Markets for Years
2003, 2008 & 2012 (includes corresponding Graph/Chart) III-50
4c. The United Kingdom III-51
A.Market Analysis III-51
Product Launches III-51
Strategic Corporate Developments III-52
GE Healthcare Ltd - A Key Player III-53
B.Market Analytics III-53
Table 35: UK Recent Past, Current & Future Analysis for
Biochips by Product Segment - DNA Chips, Protein Chips and
Lab Chips Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2000 through 2010
(includes corresponding Graph/Chart) III-53
Table 36: UK Long-Term Projections for Biochips by Product
Segment - DNA Chips, Protein Chips and Lab Chips Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) III-54
Table 37: UK 10-Year Perspective for Biochips by Product
Segment - Percentage Breakdown of Dollar Sales for DNA
Chips, Protein Chips and Lab Chips Markets for Years 2003,
2008 & 2012 (includes corresponding Graph/Chart) III-54
4d. Rest of Europe III-55
A.Market Analysis III-55
Status of Proteomics in Finland III-55
Product Developments/Launches III-55
Strategic Corporate Developments III-57
B.Market Analytics III-59
Table 38: Rest of Europe Recent Past, Current & Future
Analysis for Biochips by Product Segment - DNA Chips Protein
Chips and Lab Chips Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2000 through
2010 (includes corresponding Graph/Chart) III-59
Table 39: Rest of Europe Long-Term Projections for Biochips
by Product Segment - DNA Chips, Protein Chips and Lab Chips
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) III-60
Table 40: Rest of Europe10-Year Perspective for Biochips by
Product Segment - Percentage Breakdown of Dollar Sales for
DNA Chips, Protein Chips and Lab Chips Markets for Years
2003, 2008 & 2012 (includes corresponding Graph/Chart) III-61
5. Rest of World III-62
A.Market Analysis III-62
China III-62
Basic Environment and Commercial Development III-62
Biochip Research III-62
Status of Biochip Industry in China III-63
Historic Review - Chinese Government Chips in III-63
Novel Technologies - Top on China’s Agenda III-64
Taiwan III-64
Taiwan Pursues Promise of Biochip Sector III-64
International Advantage Sought III-64
Strategic Corporate Developments III-65
B.Market Analytics III-69
Table 41: Rest of World Recent Past, Current & Future
Analysis for Biochips by Product Segment - DNA Chips
Protein Chips and Lab Chips Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2000
through 2010 (includes corresponding Graph/Chart) III-69
Table 42: Rest of World Long-Term Projections for Biochips
by Product Segment - DNA Chips, Protein Chips and Lab Chips
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) III-70
Table 43: Rest of World 10-Year Perspective for Biochips by
Product Segment - Percentage Breakdown of Dollar Sales for
DNA Chips, Protein Chips and Lab Chips Markets for Years
2003, 2008 & 2012 (includes corresponding Graph/Chart) III-71
IV. COMPETITIVE LANDSCAPE
